Cargando…
Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria: An Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) substudy
OBJECTIVE: We tested whether long-term treatment with the angiotensin II receptor antagonist irbesartan reduces nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria. RESEARCH DESIGN AND METHODS: The Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) stu...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114487/ https://www.ncbi.nlm.nih.gov/pubmed/21454798 http://dx.doi.org/10.2337/dc10-2214 |
_version_ | 1782206070650830848 |
---|---|
author | Broedbaek, Kasper Henriksen, Trine Weimann, Allan Petersen, Morten Andersen, Jon T. Afzal, Shoaib Jimenez-Solem, Espen Persson, Frederik Parving, Hans-Henrik Rossing, Peter Poulsen, Henrik E. |
author_facet | Broedbaek, Kasper Henriksen, Trine Weimann, Allan Petersen, Morten Andersen, Jon T. Afzal, Shoaib Jimenez-Solem, Espen Persson, Frederik Parving, Hans-Henrik Rossing, Peter Poulsen, Henrik E. |
author_sort | Broedbaek, Kasper |
collection | PubMed |
description | OBJECTIVE: We tested whether long-term treatment with the angiotensin II receptor antagonist irbesartan reduces nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria. RESEARCH DESIGN AND METHODS: The Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) study was a 2-year multicenter randomized double-blind trial comparing irbesartan (150 and 300 mg once daily) with placebo. We studied a subgroup of 50 patients where urine samples were available for analysis of albumin and the oxidatively modified guanine nucleosides 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) and 8-oxo-7,8-dihydroguanosine (8-oxoGuo). RESULTS: During the 2-year trial, no significant differences in 8-oxodG and 8-oxoGuo excretions between placebo and irbesartan treatment were seen. 8-oxodG and albumin excretion decreased with time (P = 0.0004 and P < 0.0001, respectively), whereas treatment-related differences were shown for albumin excretion (P = 0.0008) only, as previously reported. Important secondary findings were significant associations between changes in 8-oxodG excretion and changes in albumin excretion and glycated hemoglobin (HbA(1c)). During the study period, 8-oxodG excretion decreased by 3 and 26% in smokers and nonsmokers, respectively (P = 0.015), and urinary albumin excretion decreased 22% in smokers and 58% in nonsmokers (P = 0.011). CONCLUSIONS: Irbesartan treatment was not significantly more effective than placebo in reducing nucleic acid oxidation. The results indicate that DNA oxidation in diabetes patients is reduced by various components in the treatment of diabetes where glycemic control seems to be important and addition of angiotensin II receptor antagonists does not lead to any substantial additional reduction. Furthermore, the reductions in DNA oxidation and albumin excretion seem to be counteracted by smoking. |
format | Online Article Text |
id | pubmed-3114487 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-31144872012-05-01 Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria: An Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) substudy Broedbaek, Kasper Henriksen, Trine Weimann, Allan Petersen, Morten Andersen, Jon T. Afzal, Shoaib Jimenez-Solem, Espen Persson, Frederik Parving, Hans-Henrik Rossing, Peter Poulsen, Henrik E. Diabetes Care Original Research OBJECTIVE: We tested whether long-term treatment with the angiotensin II receptor antagonist irbesartan reduces nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria. RESEARCH DESIGN AND METHODS: The Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) study was a 2-year multicenter randomized double-blind trial comparing irbesartan (150 and 300 mg once daily) with placebo. We studied a subgroup of 50 patients where urine samples were available for analysis of albumin and the oxidatively modified guanine nucleosides 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) and 8-oxo-7,8-dihydroguanosine (8-oxoGuo). RESULTS: During the 2-year trial, no significant differences in 8-oxodG and 8-oxoGuo excretions between placebo and irbesartan treatment were seen. 8-oxodG and albumin excretion decreased with time (P = 0.0004 and P < 0.0001, respectively), whereas treatment-related differences were shown for albumin excretion (P = 0.0008) only, as previously reported. Important secondary findings were significant associations between changes in 8-oxodG excretion and changes in albumin excretion and glycated hemoglobin (HbA(1c)). During the study period, 8-oxodG excretion decreased by 3 and 26% in smokers and nonsmokers, respectively (P = 0.015), and urinary albumin excretion decreased 22% in smokers and 58% in nonsmokers (P = 0.011). CONCLUSIONS: Irbesartan treatment was not significantly more effective than placebo in reducing nucleic acid oxidation. The results indicate that DNA oxidation in diabetes patients is reduced by various components in the treatment of diabetes where glycemic control seems to be important and addition of angiotensin II receptor antagonists does not lead to any substantial additional reduction. Furthermore, the reductions in DNA oxidation and albumin excretion seem to be counteracted by smoking. American Diabetes Association 2011-05 2011-04-20 /pmc/articles/PMC3114487/ /pubmed/21454798 http://dx.doi.org/10.2337/dc10-2214 Text en © 2011 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details. |
spellingShingle | Original Research Broedbaek, Kasper Henriksen, Trine Weimann, Allan Petersen, Morten Andersen, Jon T. Afzal, Shoaib Jimenez-Solem, Espen Persson, Frederik Parving, Hans-Henrik Rossing, Peter Poulsen, Henrik E. Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria: An Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) substudy |
title | Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria: An Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) substudy |
title_full | Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria: An Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) substudy |
title_fullStr | Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria: An Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) substudy |
title_full_unstemmed | Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria: An Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) substudy |
title_short | Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria: An Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) substudy |
title_sort | long-term effects of irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an irbesartan in patients with type 2 diabetes and microalbuminuria (irma 2) substudy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114487/ https://www.ncbi.nlm.nih.gov/pubmed/21454798 http://dx.doi.org/10.2337/dc10-2214 |
work_keys_str_mv | AT broedbaekkasper longtermeffectsofirbesartantreatmentandsmokingonnucleicacidoxidationinpatientswithtype2diabetesandmicroalbuminuriaanirbesartaninpatientswithtype2diabetesandmicroalbuminuriairma2substudy AT henriksentrine longtermeffectsofirbesartantreatmentandsmokingonnucleicacidoxidationinpatientswithtype2diabetesandmicroalbuminuriaanirbesartaninpatientswithtype2diabetesandmicroalbuminuriairma2substudy AT weimannallan longtermeffectsofirbesartantreatmentandsmokingonnucleicacidoxidationinpatientswithtype2diabetesandmicroalbuminuriaanirbesartaninpatientswithtype2diabetesandmicroalbuminuriairma2substudy AT petersenmorten longtermeffectsofirbesartantreatmentandsmokingonnucleicacidoxidationinpatientswithtype2diabetesandmicroalbuminuriaanirbesartaninpatientswithtype2diabetesandmicroalbuminuriairma2substudy AT andersenjont longtermeffectsofirbesartantreatmentandsmokingonnucleicacidoxidationinpatientswithtype2diabetesandmicroalbuminuriaanirbesartaninpatientswithtype2diabetesandmicroalbuminuriairma2substudy AT afzalshoaib longtermeffectsofirbesartantreatmentandsmokingonnucleicacidoxidationinpatientswithtype2diabetesandmicroalbuminuriaanirbesartaninpatientswithtype2diabetesandmicroalbuminuriairma2substudy AT jimenezsolemespen longtermeffectsofirbesartantreatmentandsmokingonnucleicacidoxidationinpatientswithtype2diabetesandmicroalbuminuriaanirbesartaninpatientswithtype2diabetesandmicroalbuminuriairma2substudy AT perssonfrederik longtermeffectsofirbesartantreatmentandsmokingonnucleicacidoxidationinpatientswithtype2diabetesandmicroalbuminuriaanirbesartaninpatientswithtype2diabetesandmicroalbuminuriairma2substudy AT parvinghanshenrik longtermeffectsofirbesartantreatmentandsmokingonnucleicacidoxidationinpatientswithtype2diabetesandmicroalbuminuriaanirbesartaninpatientswithtype2diabetesandmicroalbuminuriairma2substudy AT rossingpeter longtermeffectsofirbesartantreatmentandsmokingonnucleicacidoxidationinpatientswithtype2diabetesandmicroalbuminuriaanirbesartaninpatientswithtype2diabetesandmicroalbuminuriairma2substudy AT poulsenhenrike longtermeffectsofirbesartantreatmentandsmokingonnucleicacidoxidationinpatientswithtype2diabetesandmicroalbuminuriaanirbesartaninpatientswithtype2diabetesandmicroalbuminuriairma2substudy |